Arrowhead Pharmaceuticals Inc (STU:HDP1)
€ 18.885 -0.48 (-2.48%) Market Cap: 2.34 Bil Enterprise Value: 2.05 Bil PE Ratio: 0 PB Ratio: 7.70 GF Score: 49/100

Q3 2024 Arrowhead Pharmaceuticals Inc Earnings Call Transcript

Aug 08, 2024 / 08:30PM GMT
Release Date Price: €22.74 (-0.87%)
Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. (Operator Instructions)

I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Vincent Anzalone
Arrowhead Pharmaceuticals Inc - Investor Relations

Thank you. And good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's Results for its fiscal 2024 third quarter ended June 30, 2024.

With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter; Dr. Bruce Given, Interim Chief Medical Scientist, who will provide an update on our cardiometabolic pipeline, Andy Davis, Senior Vice President and Head of Global cardiometabolic franchise, who will provide an update on commercial activities; and Ken Myszkowski, Chief Financial Officer, who will give a review of the financials. Dr. James Hamilton, Chief of Discovery and Translational Medicine; and Patrick O'Brien, COO and General Counsel, will also be available during

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot